Sagimet Biosciences schedules virtual KOL event on denifanstat acne program
SGMT•Sagimet Biosciences will hold a virtual event on September 30, 2026, focused on 52-week Phase 3 open-label extension data from China and an update on its planned U.S. AURORA Phase 3 acne trial, whose initiation is targeted for Q4 2026.
1. Event details
Sagimet Biosciences scheduled a virtual KOL event on denifanstat for September 30, 2026, at 1:00 p.m. ET. The event will focus on 52-week Phase 3 open-label extension data from China and an update on the planned U.S. AURORA Phase 3 acne trial; trial initiation is targeted for Q4 2026.
